161 related articles for article (PubMed ID: 30978434)
21. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
23. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
24. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
26. A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of autologous stem cell transplantation in first remission on outcome.
Fanin R; Sperotto A; Ruiz De Elvira C; Zaja F; Stocchi R; Geromin A; Cerno M; Patriarca F; Fanni Canelles M; Damiani D; Baccarani M
Haematologica; 2000 Sep; 85(9):943-51. PubMed ID: 10980633
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
28. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
29. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest.
Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD
J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Infused Autograft Absolute Numbers of Immune Effector Cells on Survival Post-Autologous Stem Cell Transplantation.
Porrata LF
Cells; 2022 Jul; 11(14):. PubMed ID: 35883639
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
32. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation.
Porrata LF; Gastineau DA; Padley D; Bundy K; Markovic SN
Leuk Lymphoma; 2003 Jun; 44(6):997-1000. PubMed ID: 12854901
[TBL] [Abstract][Full Text] [Related]
33. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma.
Yoong Y; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Litzow MR; Gertz MA; Lacy MQ; Dispenzieri A; Gastineau DA; Tefferi A; Elliott M; Snow DS; Hogan WJ; Markovic SN
Leuk Lymphoma; 2005 Sep; 46(9):1287-94. PubMed ID: 16109605
[TBL] [Abstract][Full Text] [Related]
34. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
35. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
Williams CD; Harrison CN; Lister TA; Norton AJ; Blystad AK; Coiffier B; Taghipour G; Schmitz N; Goldstone AH;
J Clin Oncol; 2001 Feb; 19(3):727-35. PubMed ID: 11157024
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
37. Conventional allograft and autograft in low grade lymphoma.
Avivi I; Goldstone AH
Best Pract Res Clin Haematol; 2005 Mar; 18(1):113-28. PubMed ID: 15694188
[TBL] [Abstract][Full Text] [Related]
38. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
Gazitt Y; Akay C; Thomas C
Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
[TBL] [Abstract][Full Text] [Related]
39. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
40. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
